Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 5/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21880548 | 1.00 | FASN (0.36) | FASNCACNA1HTLR9TLR8TLR7 | |
| SCHEMBL21942480 | 0.86 | MAPT (0.35) | CACNA1HAKR1B1 | |
| SCHEMBL17410764 | 0.84 | FASN (0.53) | FASN | |
| SCHEMBL22837423 | 0.81 | FASN (0.34) | FASNHSD11B1 | |
| SCHEMBL17410776 | 0.81 | FASN (0.48) | FASNPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL16156057 | 0.80 | FASN (0.41) | FASN | |
| SCHEMBL17410879 | 0.77 | FASN (0.44) | FASNPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL17410670 | 0.77 | FASN (0.53) | FASN | |
| SCHEMBL17410837 | 0.77 | GHSR (0.43) | FASN | |
| SCHEMBL17410750 | 0.77 | FASN (0.40) | FASNPRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| EP-3636637-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | Forma Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | FASN 1/4885CACNA1H 3827/4885TLR9 4504/4885 |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | FASN 1/4885CACNA1H 3827/4885TLR9 4504/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | FASN 1/4885CACNA1H 3827/4885TLR9 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.